Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.
Aprogen Pharmaceuticals Inc (003060) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.024x
Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has a cash flow conversion efficiency ratio of -0.024x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-7.66 Billion) by net assets (₩315.16 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aprogen Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Aprogen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aprogen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Goodfood Market Corp
PINK:GDDFF
|
-0.026x |
|
Gamehaus Holdings Inc. Class A Ordinary Shares
NASDAQ:GMHS
|
-0.015x |
|
MARKEL CORP (MKV.SG)
STU:MKV
|
0.050x |
|
Central Motek Co Ltd
KO:308170
|
0.139x |
|
Plantynet Co. Ltd
KQ:075130
|
-0.015x |
|
Giyani Metals Corp
PINK:CATPF
|
-0.058x |
|
Global Education Limited
NSE:GLOBAL
|
0.078x |
|
Dongyang Piston Co Ltd
KO:092780
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Aprogen Pharmaceuticals Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Aprogen Pharmaceuticals Inc from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩378.69 Billion | ₩-31.00 Billion | -0.082x | +10.32% |
| 2023-12-31 | ₩368.69 Billion | ₩-33.65 Billion | -0.091x | -281.07% |
| 2022-12-31 | ₩510.41 Billion | ₩25.73 Billion | 0.050x | +583.45% |
| 2021-12-31 | ₩597.18 Billion | ₩-6.23 Billion | -0.010x | -177.13% |
| 2020-12-31 | ₩598.36 Billion | ₩8.09 Billion | 0.014x | +558.38% |
| 2019-12-31 | ₩347.64 Billion | ₩713.73 Million | 0.002x | -76.79% |
| 2018-12-31 | ₩150.51 Billion | ₩1.33 Billion | 0.009x | +107.71% |
| 2017-12-31 | ₩77.86 Billion | ₩-8.93 Billion | -0.115x | -2090.66% |
| 2016-12-31 | ₩78.12 Billion | ₩449.98 Million | 0.006x | -78.87% |
| 2015-12-31 | ₩67.75 Billion | ₩1.85 Billion | 0.027x | +124.48% |
| 2014-12-31 | ₩62.11 Billion | ₩-6.92 Billion | -0.111x | -270.03% |
| 2013-12-31 | ₩56.55 Billion | ₩-1.70 Billion | -0.030x | -619.64% |
| 2010-12-31 | ₩42.81 Billion | ₩247.92 Million | 0.006x | -- |